Abstract
BackgroundMethotrexate (MTX) is widely used as a disease modifying agent in rheumatic disease.1 The National Patient Safety Agency (UK) have previously highlighted the potential hazards of MTX therapy and requested...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
